MGUSP-RODS

  • Research type

    Research Study

  • Full title

    The development of a Monoclonal Gammopathy of Undetermined Significance Polyneuropathy Rasch-Built Disability Scale (the MGUSP-RODS)for clinical and trial use.

  • IRAS ID

    199071

  • Contact name

    M.P.T. Lunn

  • Contact email

    michael.lunn@uclh.nhs.uk

  • Sponsor organisation

    University College London

  • Clinicaltrials.gov Identifier

    Z6364106/2016/03/114, UCL Data Protection Registration Number

  • Duration of Study in the UK

    0 years, 6 months, 0 days

  • Research summary

    Monoclonal gammopathy of undetermined significance polyneuropathy (MGUSP) is a slowly progressive disease of the nerves accompanied by an increased protein in the blood. It has differential effects in individuals ranging from mild foot numbness and minor imbalance to severe neuropathic pain and sensory and motor dysfunction. These symptoms lead to functional deficit and reduced quality of life. International consensus on how to assess functional deficits in patients with MGUSP is lacking. A new MGUSP-specific and more sensitive patient-based outcome measure needs to be constructed. This outcome measure could serve to assess the natural course of the disease and as the primary outcome in future trials. This study aims to develop an MGUSP-specific outcome measure using obtained knowledge on modern scientific scales construction in other peripheral neuropathies. Approximately 100 patients with MGUSP in the National Hospital for Neurology and Neurosurgery in London will be included. Patients will be asked to fill in a questionnaire containing 146 questions concerning activities of daily living twice, with an interval of 2-4 weeks. Modern statistical analysis will be used in order to construct the final questionnaire fulfilling all modern clinimetric requirements, like being simple, valid, reliable, and responsive.

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    16/NW/0901

  • Date of REC Opinion

    17 Oct 2017

  • REC opinion

    Further Information Favourable Opinion